Argenx is a biopharmaceutical company that develops antibody-based medicines for serious autoimmune diseases. Its main commercial product is an antibody fragment designed to reduce disease-causing antibodies, used in the treatment of generalized myasthenia gravis and other autoimmune conditions. The company carries out research and clinical development and sells its medicines through its own commercial organization. Argenx is headquartered in the Netherlands, with a significant presence in Belgium and the United States, and serves patients and physicians in multiple markets around the world.
On this site Argen-X appears as a stock on the Euronext Brussels (Belgium), code ARGX, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Strong price profile
Ranks #17 of 111 on the Euronext Brussels · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Belgium yet.
TrendStrong
78/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average5.8%
From 52-week high-14.1%
MomentumStrong
81/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return3.3%
6-month return15.5%
12-month, skipping last month20.6%
Stability (higher is calmer)Weak
35/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)39.8%
Worst drawdown, 1 year (smaller is calmer)-27.4%
LiquidityStrong
100/100
Trades actively.
See the numbers →
Avg daily value traded70.20M EUR
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Belgium when fundamentals data for this market is added. All Belgium stocks.
52-wk range 568.40 – 925.00Daily closes, split-adjusted
Signals
50-day average835.54
200-day average740.43
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)32.27
Technical summary
Daily
Neutral
5 bullish · 4 neutral · 7 bearish
Weekly
Bullish
7 bullish · 1 neutral · 4 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
SMA 10
749.3
Bullish
EMA 10
767.5
Bullish
SMA 20
786.3
Bearish
EMA 20
782.7
Bullish
SMA 50
835.5
Bearish
EMA 50
803.5
Bearish
SMA 100
804.0
Bearish
EMA 100
791.7
Bearish
SMA 200
740.4
Bullish
EMA 200
755.0
Bullish
Oscillators (daily)
RSI (14)
48.19
Neutral
MACD (12, 26)
-21.01
Bearish
Momentum (12)
-6.16
Bearish
Stochastic %K (14)
64.18
Neutral
Williams %R (14)
-35.82
Neutral
CCI (20)
-10.29
Neutral
Pivot points (classic, last session)
S3
709.1
S2
731.3
S1
757.3
Pivot
779.5
R1
805.5
R2
827.7
R3
853.7
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in EUR. Educational only, not financial advice.
